Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
MetaVia ( (MTVA) ) has shared an update.
MetaVia Inc. announced positive results from its Phase 2a clinical trial of DA-1241 in patients with presumed MASH, demonstrating significant improvements in liver enzymes and glucose levels. The trial’s success suggests DA-1241 could be a safe and effective treatment option for MASH, with further studies and an FDA meeting planned for 2025.
More about MetaVia
MetaVia Inc., a clinical-stage biotechnology company, is focused on transforming cardiometabolic diseases.
YTD Price Performance: -39.24%
Average Trading Volume: 41,295
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $19.37M
See more insights into MTVA stock on TipRanks’ Stock Analysis page.
